What are the major opportunities in the HER2-Negative Breast Cancer market? What are the strategies for the HER2-Negative Breast Cancer market?

For detailed insights on the major opportunities and strategies in the HER2-Negative Breast Cancer market, Read More

How does the HER2-Negative Breast Cancer market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the HER2-Negative Breast Cancer market growth and SWOT analysis of the HER2-Negative Breast Cancer industry, Read More

For detailed insights on the mergers and acquisitions in the HER2-Negative Breast Cancer industry,

What are the key dynamics influencing the HER2-Negative Breast Cancer market growth? SWOT analysis of the HER2-Negative Breast Cancer market. Read More

Global HER2-Negative Breast Cancer Market Report 2025

Item added to cart!

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF

Purchase This Report

HER2-Negative Breast Cancer Global Market Report 2025

Name: HER2-Negative Breast Cancer Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy), By Cancer Stage (Early Stage, Locally Advanced Stage, Metastatic Stage), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

HER2-Negative Breast Cancer Market Overview

• HER2-Negative Breast Cancer market size has reached to $16.29 billion in 2024

• Expected to grow to $23.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%

• Growth Driver: Rising Breast Cancer Incidence Drives Growth Of The Market

• Market Trend: Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2-Negative Breast Cancer Market?

HER2-negative breast cancer refers to a type of breast cancer where the cancer cells do not have high levels of the HER2 protein, which promotes tumour growth. This type of cancer tends to grow more slowly than HER2-positive breast cancer and is treated with targeted therapies and chemotherapy.

The main treatment types of HER2-negative breast cancer are chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy refers to a type of cancer treatment that uses powerful drugs to kill or inhibit the growth of cancer cells by targeting and destroying rapidly dividing cells in the body. It includes different stages, including early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

HER2-Negative Breast Cancer Market Size and growth rate 2025 to 2029: Graph

What Is The HER2-Negative Breast Cancer Market Size 2025 And Growth Rate?

The HER2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to the rise in breast cancer cases, increased awareness about breast cancer, increased spending on healthcare, an aging population, and expanding healthcare infrastructures.

What Is The HER2-Negative Breast Cancer Market Growth Forecast?

The HER2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $23.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing consumption of alcohol, increasing adoption of unhealthy lifestyles, increasing prevalence of obesity, increasing consumption of tobacco, and increasing need for effective treatment solutions. Major trends in the forecast period include innovations in diagnostic technologies, integration of targeted therapies, integration of immunotherapies, FDA approvals, and technological advancements.

The forecast of 7.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of CDK4/6 inhibitors (e.g., palbociclib) and PARP inhibitors sourced from the UK and Singapore, thereby delaying metastatic disease control and elevating oncology pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The HER2-Negative Breast Cancer Market Segmented?

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Is Driving The HER2-Negative Breast Cancer Market? Rising Breast Cancer Incidence Drives Growth Of The Market

Rising incidence of breast cancer cases is expected to propel the growth of the HER2-negative breast cancer market going forward. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, commonly originating in the ducts or lobules. The rising incidence of breast cancer cases can be attributed to several factors, including increased awareness and improved screening methods, leading to earlier and more frequent detection. HER2-Negative Breast Cancer plays a crucial role in advancing breast cancer research by providing insights into distinct tumor biology and treatment strategies, contributing to the development of more targeted therapies for patients. For instance, in June 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, in the United States, 272,454 new cases of breast cancer were diagnosed among females in 2021, while 42,211 females succumbed to the disease in 2022. Therefore, the rising incidence of breast cancer cases is driving the growth of the HER2-negative breast cancer industry.

Who Are The Major Players In The Global HER2-Negative Breast Cancer Market?

Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

What Are The Key Trends Of The Global HER2-Negative Breast Cancer Market? Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments

Major companies operating in the HER2-negative breast cancer market are focusing on securing regulatory approvals to introduce new treatments, expand their product portfolios, and enhance their market presence. Regulatory approvals refer to the official authorization granted by government agencies, allowing companies to market and distribute drugs or treatments after meeting safety, efficacy, and quality standards. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, received FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval allows Itovebi to be used in combination with palbociclib and fulvestrant, significantly improving progression-free survival for patients compared to standard treatments. This new regimen provides a vital option for patients facing limited treatment choices, emphasizing the importance of biomarker testing to identify those who would benefit most from this therapy.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The HER2-Negative Breast Cancer Market? Relay And Pfizer Collaborate To Target Her2-negative Breast Cancer

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, collaborated with Pfizer Inc. This collaboration is aimed at evaluating atirimociclib, Pfizer’s investigative selective CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. This collaboration also aims to leverage the unique properties of both drugs to minimize off-target toxicity that has limited the efficacy of non-selective agents in the past. Pfizer Inc. is a US-based pharmaceutical and biotechnology corporation actively involved in the treatment of HER2-negative breast cancer.

What Is The Regional Outlook For The Global HER2-Negative Breast Cancer Market?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Negative Breast Cancer Market?

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the HER2-Negative Breast Cancer Industry?

The her2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the her2-negative breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

HER2Negative Breast Cancer Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$17.57 billion
Revenue Forecast In 2034	$23.67 billion
Growth Rate	CAGR of 7.7% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The HER2-negative breast cancer market covered in this report is segmented – 1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy 2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites 2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs) 3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors 4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. HER2-Negative Breast Cancer Market Characteristics

3. HER2-Negative Breast Cancer Market Trends And Strategies

4. HER2-Negative Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global HER2-Negative Breast Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global HER2-Negative Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global HER2-Negative Breast Cancer Market Growth Rate Analysis

5.4. Global HER2-Negative Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global HER2-Negative Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global HER2-Negative Breast Cancer Total Addressable Market (TAM)

6. HER2-Negative Breast Cancer Market Segmentation

6.1. Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Chemotherapy

Hormone Therapy

Targeted Therapy

Immunotherapy

6.2. Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Early Stage

Locally Advanced Stage

Metastatic Stage

6.3. Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.4. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anthracyclines

Taxanes

Platinum-Based Chemotherapy

Alkylating Agents

Antimetabolites

6.5. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Selective Estrogen Receptor Modulators (SERMs)

Aromatase Inhibitors

Selective Estrogen Receptor Degraders (SERDs)

6.6. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

CDK4/6 Inhibitors

PI3K Inhibitors

PARP Inhibitors

6.7. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immune Checkpoint Inhibitors

Tumor-Infiltrating Lymphocyte (TIL) Therapy

7. HER2-Negative Breast Cancer Market Regional And Country Analysis

7.1. Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2-Negative Breast Cancer Market

8.1. Asia-Pacific HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2-Negative Breast Cancer Market

9.1. China HER2-Negative Breast Cancer Market Overview

9.2. China HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2-Negative Breast Cancer Market

10.1. India HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2-Negative Breast Cancer Market

11.1. Japan HER2-Negative Breast Cancer Market Overview

11.2. Japan HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2-Negative Breast Cancer Market

12.1. Australia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2-Negative Breast Cancer Market

13.1. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2-Negative Breast Cancer Market

14.1. South Korea HER2-Negative Breast Cancer Market Overview

14.2. South Korea HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2-Negative Breast Cancer Market

15.1. Western Europe HER2-Negative Breast Cancer Market Overview

15.2. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2-Negative Breast Cancer Market

16.1. UK HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2-Negative Breast Cancer Market

17.1. Germany HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2-Negative Breast Cancer Market

18.1. France HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2-Negative Breast Cancer Market

19.1. Italy HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2-Negative Breast Cancer Market

20.1. Spain HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2-Negative Breast Cancer Market

21.1. Eastern Europe HER2-Negative Breast Cancer Market Overview

21.2. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2-Negative Breast Cancer Market

22.1. Russia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2-Negative Breast Cancer Market

23.1. North America HER2-Negative Breast Cancer Market Overview

23.2. North America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2-Negative Breast Cancer Market

24.1. USA HER2-Negative Breast Cancer Market Overview

24.2. USA HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2-Negative Breast Cancer Market

25.1. Canada HER2-Negative Breast Cancer Market Overview

25.2. Canada HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2-Negative Breast Cancer Market

26.1. South America HER2-Negative Breast Cancer Market Overview

26.2. South America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2-Negative Breast Cancer Market

27.1. Brazil HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2-Negative Breast Cancer Market

28.1. Middle East HER2-Negative Breast Cancer Market Overview

28.2. Middle East HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2-Negative Breast Cancer Market

29.1. Africa HER2-Negative Breast Cancer Market Overview

29.2. Africa HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2-Negative Breast Cancer Market Competitive Landscape And Company Profiles

30.1. HER2-Negative Breast Cancer Market Competitive Landscape

30.2. HER2-Negative Breast Cancer Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. HER2-Negative Breast Cancer Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. AstraZeneca PLC

31.3. Novartis International AG

31.4. Eli Lilly and Company

31.5. Amgen Inc.

31.6. Daiichi Sankyo Company Limited

31.7. Jiangsu Hansoh Pharmaceutical Co. Ltd.

31.8. BeiGene Ltd.

31.9. Chipscreen Biosciences Ltd.

31.10. F. Hoffmann-La Roche Ltd

31.11. PharmAbcine Inc.

31.12. Adagene Inc.

31.13. H3 Biomedicine Inc.

31.14. Radius Health Inc.

31.15. Zenith Epigenetics Ltd.

32. Global HER2-Negative Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2-Negative Breast Cancer Market

34. Recent Developments In The HER2-Negative Breast Cancer Market

35. HER2-Negative Breast Cancer Market High Potential Countries, Segments and Strategies

35.1 HER2-Negative Breast Cancer Market In 2029 - Countries Offering Most New Opportunities

35.2 HER2-Negative Breast Cancer Market In 2029 - Segments Offering Most New Opportunities

35.3 HER2-Negative Breast Cancer Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: Merck & Co. Inc. Financial Performance

Table 80: AbbVie Inc. Financial Performance

Table 81: Bayer AG Financial Performance

Table 82: Bristol-Myers Squibb Company Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: Merck & Co. Inc. Financial Performance

Figure 80: AbbVie Inc. Financial Performance

Figure 81: Bayer AG Financial Performance

Figure 82: Bristol-Myers Squibb Company Financial Performance

Top Trends Driving Innovation and Change in the Interstitial Lung Disease Market: Innovative Drug Development Initiatives To Improve Interstitial Lung Disease Treatment

Global Intestinal Pseudo-Obstruction Treatment Market Projected to Reach $30.8 Billion by 2029 at a CAGR of 5.6%

Key Developments and Trends Steering the Intestine Cancer Therapeutics Market Forward: Increasing Focus On Product Approvals To Drive The Revenues

Major Trends and Emerging Patterns in the Intravenous Solutions Market: Innovative Syringes Transforming The Intravenous Solutions Market

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Breast Cancer Drugs Global Market Report 2025 – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer Duri...

Metastatic HR+/HER2- Breast Cancer Global Market Report 2025 – By Drugs (Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel, Other Drugs), By Treatment (Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeo...

Breast Cancer Diagnostics Global Market Report 2025 – By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types), By Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), ...

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Testing, Magn...

Metastatic Breast Cancer Treatment Global Market Report 2025 – By Therapy Type (Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy), By Molecule Type (Monoclonal Antibody, Peptide...

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Global Market Report 2025 - By Therapy Type (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiati...

Anti-Cancer MAbS Global Market Report 2025 – By Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liv...

Frequently Asked Questions

What is the definition of the HER2-Negative Breast Cancer market?

How will the HER2-Negative Breast Cancer market drivers and restraints affect the market dynamics? What forces will shape the HER2-Negative Breast Cancer industry going forward?

The market major growth driver - Rising Breast Cancer Incidence Drives Growth Of The Market. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the HER2-Negative Breast Cancer market?

The her2-negative breast cancer market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.57 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to the rise in breast cancer cases, increased awareness about breast cancer, increased spending on healthcare, an aging population, and expanding healthcare infrastructures. The her2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to " $23.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing consumption of alcohol, increasing adoption of unhealthy lifestyles, increasing prevalence of obesity, increasing consumption of tobacco, and increasing need for effective treatment solutions. Major trends in the forecast period include innovations in diagnostic technologies, integration of targeted therapies, integration of immunotherapies, FDA approvals, and technological advancements. For further insights on this market, request a sample here

How is the HER2-Negative Breast Cancer market segmented?

The her2-negative breast cancermarket covered in this report is segmented –
1) By Treatment Type: Chemotherapy; Hormone Therapy; Targeted Therapy; Immunotherapy
2) By Cancer Stage: Early Stage; Locally Advanced Stage; Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy Subsegments:
1) By Chemotherapy: Anthracyclines; Taxanes; Platinum-Based Chemotherapy; Alkylating Agents; Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors; PI3K Inhibitors; PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors; Tumor-Infiltrating Lymphocyte (TIL) Therapy For further insights on this market, request a sample here

Which region has the largest share of the HER2-Negative Breast Cancer market? What are the other regions covered in the report?

North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the HER2-Negative Breast Cancer market?

What are the key trends in the HER2-Negative Breast Cancer market?

Major trends in this market include Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments. For further insights on this market, request a sample here.